Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Steven Coca DO, MS

Steven G. Coca DO, MS

Associate Chair for Clinical and Translational Research, Department of Internal Medicine; Professor of Medicine, Division of Nephrology, Department of Internal Medicine, Icahn School of Medicine at Mount Sinai, New York, New York

Steven G. Coca, DO, is a graduate of the University of New England College of Osteopathic Medicine. He completed his medical residency and clinical nephrology fellowship at Yale University and Yale New Haven Hospital in Connecticut. He also received a Master’s Degree in Epidemiology and Public Health during his training at Yale. There, he later served as an Assistant Professor in the Section of Nephrology, until his recruitment to Mount Sinai in 2014 as Associate Professor. He is the Director for Clinical Research for the Division of Nephrology and is the Associate Chair for Clinical and Translational Research for the Department of Medicine at the Icahn School of Medicine at Mount Sinai.

His research has focused on using novel biomarkers to improve risk stratification in patients with acute kidney injury and patients at risk or with prevalent chronic kidney disease. He has been continually funded by the NIH over the last decade for multiple biomarker-related projects and consortia. He is the co-founder of RenalytixAI.

Disclosures

Dr. Coca reports the following:

Consultancy Agreements: RenalytixAI, Takeda, CHF Solutions, Relypsa, Bayer, Boehringer Ingelheim, Quark, Akebia

Ownership Interest: RenalytixAI, pulseData

Research Funding: RenalytixAI, inRegen

Patents and Inventions: RenalytixAI

Scientific Advisor or Membership: RenalytixAI

Other Interests/Relationships: Associate Editor for Kidney360, Editorial Board JASN, CJASN, Kidney International

Recent Contributions to PracticeUpdate:

  1. Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients With Type 2 Diabetes
  2. Optimization of Albuminuria-Lowering Treatment in Diabetes by Crossover Rotation to Four Different Drug Classes
  3. Initial Decline in eGFR After Dapagliflozin Initiation and Its Associated Outcomes in Patients With HFrEF
  4. Finerenone Reduces CV and Kidney Outcomes Risk in Patients With Type 2 Diabetes and CKD
  5. Dapagliflozin in Patients With Chronic Kidney Disease
  6. SGLT2 Inhibition for the Prevention of Diabetic Kidney Disease
  7. Canagliflozin Improves Renal Outcomes in Type 2 Diabetes
  8. Effects of the SGLT2 Inhibitor Dapagliflozin on Glomerular and Tubular Injury Markers
  9. Long-Term Follow-Up of Intensive Glycemic Control on Renal Outcomes

Most Read This Week

Recently Updated